Correlation Between Virpax Pharmaceuticals and Eyenovia
Can any of the company-specific risk be diversified away by investing in both Virpax Pharmaceuticals and Eyenovia at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Virpax Pharmaceuticals and Eyenovia into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Virpax Pharmaceuticals and Eyenovia, you can compare the effects of market volatilities on Virpax Pharmaceuticals and Eyenovia and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Virpax Pharmaceuticals with a short position of Eyenovia. Check out your portfolio center. Please also check ongoing floating volatility patterns of Virpax Pharmaceuticals and Eyenovia.
Diversification Opportunities for Virpax Pharmaceuticals and Eyenovia
0.7 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Virpax and Eyenovia is 0.7. Overlapping area represents the amount of risk that can be diversified away by holding Virpax Pharmaceuticals and Eyenovia in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eyenovia and Virpax Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Virpax Pharmaceuticals are associated (or correlated) with Eyenovia. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eyenovia has no effect on the direction of Virpax Pharmaceuticals i.e., Virpax Pharmaceuticals and Eyenovia go up and down completely randomly.
Pair Corralation between Virpax Pharmaceuticals and Eyenovia
Given the investment horizon of 90 days Virpax Pharmaceuticals is expected to generate 0.53 times more return on investment than Eyenovia. However, Virpax Pharmaceuticals is 1.89 times less risky than Eyenovia. It trades about -0.18 of its potential returns per unit of risk. Eyenovia is currently generating about -0.18 per unit of risk. If you would invest 65.00 in Virpax Pharmaceuticals on September 15, 2024 and sell it today you would lose (25.00) from holding Virpax Pharmaceuticals or give up 38.46% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Virpax Pharmaceuticals vs. Eyenovia
Performance |
| Timeline |
| Virpax Pharmaceuticals |
| Eyenovia |
Virpax Pharmaceuticals and Eyenovia Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Virpax Pharmaceuticals and Eyenovia
The main advantage of trading using opposite Virpax Pharmaceuticals and Eyenovia positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Virpax Pharmaceuticals position performs unexpectedly, Eyenovia can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eyenovia will offset losses from the drop in Eyenovia's long position.| Virpax Pharmaceuticals vs. Revelation Biosciences | Virpax Pharmaceuticals vs. Palisade Bio | Virpax Pharmaceuticals vs. Virax Biolabs Group | Virpax Pharmaceuticals vs. Quoin Pharmaceuticals Ltd |
| Eyenovia vs. Emergent Biosolutions | Eyenovia vs. Bausch Health Companies | Eyenovia vs. Neurocrine Biosciences | Eyenovia vs. Teva Pharma Industries |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Complementary Tools
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |